Table 4. Assessment of factors relative to progression-free survival.
| Group | Total | # Failed | Median survival in weeks (95% CI) | 6-month survival (95% CI) | 12-month survival (95% CI) | 24-month survival (95% CI) | Logrank p-value |
|---|---|---|---|---|---|---|---|
| Maximum tumor size ≤ 6cm | 16 | 15 | 46.6 (8.1, 63.7) | 68.8% (40.5%, 85.6%) | 43.8% (19.8%, 65.6%) | 12.5% (2.1%, 32.8%) | 0.6061 |
| Maximum tumor size > 6cm | 48 | 43 | 41.4 (31.7, 53.6) | 68.8% (53.6%, 79.8%) | 37.5% (24.1%, 50.9%) | 25% (13.9%, 37.8%) | |
| No tumor crossing the midline | 33 | 28 | 49 (31.9, 64.3) | 72.7% (54.1%, 84.8%) | 45.5% (28.2%, 61.2%) | 30.3% (15.9%, 46.1%) | 0.0917 |
| Tumor crossing the midline | 31 | 30 | 41 (24, 44.9) | 64.5% (45.2%, 78.5%) | 32.3% (16.9%, 48.6%) | 12.9% (4.1%, 27%) | |
| No presence of contrast | 35 | 30 | 51.4 (41, 63.7) | 80% (62.6%, 89.9%) | 48.6% (31.4%, 63.7%) | 28.6% (14.9%, 43.8%) | 0.0673 |
| Presence of contrast | 29 | 28 | 37.7 (23.6, 46.4) | 55.2% (35.6%, 71%) | 27.6% (13.1%, 44.3%) | 13.8% (4.3%, 28.6%) | |
| Age ≥ 40 years | 38 | 34 | 45.9 (31.7, 56) | 68.4% (51.1%, 80.7%) | 42.1% (26.4%, 57%) | 26.3% (13.7%, 40.8%) | 0.3583 |
| Age < 40 years | 26 | 24 | 42.1 (24.6, 53.6) | 69.2% (47.8%, 83.3%) | 34.6% (17.5%, 52.5%) | 15.4% (4.8%, 31.5%) | |
| KPS < 90 | 25 | 23 | 43 (24.9, 55.9) | 64% (42.2%, 79.4%) | 32% (15.2%, 50.2%) | 20% (7.3%, 37.2%) | 0.5713 |
| KPS ≥ 90 | 39 | 35 | 46.4 (31.7, 63.7) | 71.8% (54.9%, 83.3%) | 43.6% (27.9%, 58.3%) | 23.1% (11.4%, 37.1%) | |
| Astrocytoma | 32 | 29 | 43.5 (31.7, 63.7) | 71.9% (52.9%, 84.3%) | 43.8% (26.5%, 59.8%) | 21.9% (9.6%, 37.2%) | 0.9434 |
| Oligodendroglioma | 32 | 29 | 43.3 (24.9, 53.6) | 65.6% (46.6%, 79.3%) | 34.4% (18.8%, 50.6%) | 21.9% (9.6%, 37.2%) | |
| No use of EIAEDs | 43 | 39 | 44 (33, 56) | 67.4% (51.3%, 79.3%) | 41.9% (27.1%, 55.9%) | 23.3% (12%, 36.6%) | 0.8876 |
| Use of EIAEDs | 21 | 19 | 41 (24.6, 55.9) | 71.4% (47.2%, 86%) | 33.3% (14.9%, 53.1%) | 19% (5.9%, 37.7%) | |
| ≤ 1 PD | 49 | 43 | 49 (41.1, 63.7) | 75.5% (60.9%, 85.3%) | 46.9% (32.6%, 60%) | 26.5% (15.2%, 39.3%) | 0.0045 |
| >1 PD | 15 | 15 | 25.1 (15.6, 41) | 46.7% (21.2%, 68.7%) | 13.3% (2.2%, 34.6%) | 6.7% (0.4%, 26%) |
Abbreviations: CI, confidence interval; cm, centimeter; EIAED, CYP3A-enzyme inducing antiepileptic drugs; KPS, Karnofsky performance status; PD, progressive disease